Does Rallies show Form 4 insider transactions for ANIP?

Yes. Rallies tracks ANIP insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is ANIP research on Rallies investment advice?

No. Rallies provides research, data, and educational context for ANIP. It does not provide personalized investment advice.

ANIP (ANI Pharmaceuticals, Inc.) Stock Analysis - Insider Trades

ANI Pharmaceuticals, Inc. (ANIP) is a publicly traded Healthcare sector company. As of May 21, 2026, ANIP trades at $82.00 with a market cap of $1.80B and a P/E ratio of 19.96. ANIP moved +2.07% today. Year to date, ANIP is +4.25%; over the trailing twelve months it is +35.22%. Its 52-week range spans $52.50 to $99.50. Analyst consensus is strong buy with an average price target of $115.20. Rallies surfaces ANIP's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading ANIP stock inside the company?

Recent ANIP insider activity includes Walsh Patrick D sold 10.00K, Cook Meredith sold 500, Rowland Thomas Andrew sold 459, Gutwerg Ori sold 2.77K, and Walsh Patrick D sold 3.97K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

ANIP Key Metrics

Key financial metrics for ANIP
Metric	Value
Price	$82.00
Market Cap	$1.80B
P/E Ratio	19.96
EPS	$4.11
Dividend Yield	0.00%
52-Week High	$99.50
52-Week Low	$52.50
Volume	0
Avg Volume	0
Revenue (TTM)	$923.71M
Net Income	$92.15M
Gross Margin	0.00%

Recent ANIP Insider Trades

Walsh Patrick D sold 10.00K (~$806.30K) on May 13, 2026.
Cook Meredith sold 500 (~$39.08K) on May 13, 2026.
Rowland Thomas Andrew sold 459 (~$36.36K) on May 12, 2026.
Gutwerg Ori sold 2.77K (~$220.37K) on May 12, 2026.
Walsh Patrick D sold 3.97K (~$320.82K) on May 11, 2026.

Latest ANIP News

ANI Pharmaceuticals Q1 Revenue Rises 24% to $124.7M, EBITDA Climbs 30% — May 9, 2026
ANI Pharmaceuticals Launches Pimozide Tablets with 180-Day Exclusivity and $3.1M Market — Apr 20, 2026
ANI Pharmaceuticals Launches Carbamazepine ER Capsules, Targets $65M Market — Apr 13, 2026
ANI Pharmaceuticals Launches FDA-Approved 10 mg/20 mg Isosorbide Mononitrate Generics — Apr 8, 2026
Revance Plans Sales Lift for DAXXIFY as It Unifies Aesthetics and Skincare — Apr 7, 2026

ANIP Analyst Consensus

7 analysts cover ANIP: 0 strong buy, 6 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $115.20.

Common questions about ANIP

Who is trading ANIP stock inside the company?: Recent ANIP insider activity includes Walsh Patrick D sold 10.00K, Cook Meredith sold 500, Rowland Thomas Andrew sold 459, Gutwerg Ori sold 2.77K, and Walsh Patrick D sold 3.97K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for ANIP?: Yes. Rallies tracks ANIP insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is ANIP research on Rallies investment advice?: No. Rallies provides research, data, and educational context for ANIP. It does not provide personalized investment advice.